Soleno Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 5.72 million compared to USD 8.95 million a year ago. Basic loss per share from continuing operations was USD 1.05 compared to USD 1.65 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.34 USD | -5.08% | +0.51% | -7.23% |
Apr. 04 | Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing | MT |
Mar. 18 | North American Morning Briefing : Investors -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.23% | 1.25B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.79% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022